Intravaginal immunization using the recombinant HIV-1 clade-C trimeric envelope glycoprotein CN54gp140 formulated within lyophilized solid dosage forms

Vaccine

Volumn 29, Issue 27, 2011, Pages 4512-4520

  Donnelly, Louise ^a   Curran, Rhonda M ^a   Tregoning, John S ^b   McKay, Paul F ^b   Cole, Tom ^b   Morrow, Ryan J ^a   Kett, Vicky L ^a   Andrews, Gavin P ^a   Woolfson, A David ^a   Malcolm, R Karl ^a   Shattock, Robin J ^b  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

HIV 1; Intravaginal delivery; Lyophilized solid dosage formulations; Mucosal vaccination

Indexed keywords

CARBOMER; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; HYDROXYETHYLCELLULOSE; RECOMBINANT CLADE C TRIMERIC ENVELOPE GLYCOPROTEIN CN54GP140; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; AQUEOUS SOLUTION; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DILUTION; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; FEMALE; FEMALE GENITAL SYSTEM; FLOW KINETICS; FREEZE DRYING; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; SUSTAINED DRUG RELEASE; TABLET FRIABILITY; VACCINE PRODUCTION; VAGINA DISCHARGE;

ADMINISTRATION, INTRAVAGINAL; AIDS VACCINES; ANIMALS; CHEMISTRY, PHARMACEUTICAL; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; FEMALE; FREEZE DRYING; GELS; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, MUCOSAL; IMMUNIZATION; MICE; POLYVINYLS; RHEOLOGY; STARCH; VACCINES, SYNTHETIC;

EID: 79958094978     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.04.023     Document Type: Article

References (22)

1. AIDS epidemic update November 2009. UNAIDS/09.36E/JC1700E. 2009 [accessed 21.06.10]. http://data.unaids.org/pub/Report/2009/JC1700_Epi_Update_2009_en.pdf.
2. Shattock R.J., Moore J.P. Inhibiting sexual transmission of HIV-1 infection. Nat Rev Microbiol 2003, 1:25-34.
3. Miller C.J., Li Q., Abel K., Kim E.-Y., Ma Z.-M., Wietgrefe S., et al. Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus. J Virol 2005, 79:9217-9227.
4. Zhou T., Xu L., Dey B., Hessell A.J., Ryk D.V., Xiang S.-H., et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 2007, 445:732-737.
5. Waldman R.H., Cruz J.M., Rowe D.S. Intravaginal immunization of humans with Candida albicans. J Immunol 1972, 109:662-664.
6. Ogra P.L., Ogra S.S. Local Ab response to poliovaccine in the human female genital tract. J Immunol 1973, 110:1307-1311.
7. Uehling D.T., Hopkins W.J., Beierle L.M., Kryger J.V., Heisey D.M. Vaginal mucosal immunization for recurrent urinary tract infection: extended phase II clinical trial. J Infect Dis 2001, 183:S81-S83.
8. Wassen L., Schon K., Holmgren J., Jertborn M., Lycke N. Local intravaginal vaccination of the female genital tract. Scand J Immunol 1996, 44:408-414.
9. Kozlowski P.A., Cu-Uvin S., Neutra M.R., Flanigan T.P. Comparison of oral, rectal, and vaginal immunization routes for induction of antibodies in rectal and genital tract secretions of women. Infect Immun 1997, 65:1387-1394.
10. Johansson E.-L., Wassén L., Holmgren J., Jertborn M., Rudin A. Nasal and vaginal vaccinations have differential effects on Ab responses in vaginal and cervical secretions in humans. Infect Immun 2001, 69:7481-7486.
11. Kozlowski P.A., Williams S.B., Lynch R.M., Flanigan T.P., Patterson R.R., Cu-uvin S., et al. Differential induction of mucosal and systemic Ab responses in women after nasal, rectal, or vaginal immunization: influence of the menstrual cycle. J Immunol 2002, 169:566-574.
12. Andrews G.P., Donnelly L., Jones D.S., Curran R.M., Morrow R.J., Woolfson A.D., et al. Characterization of the rheological, mucoadhesive, and drug release properties of highly structured gel platforms for intravaginal drug delivery. Biomacromolecules 2009, 10:2427-2435.
13. Curran R.M., Donnelly L., Morrow R.J., Fraser C., Andrews G.P., Cranage M., et al. Vaginal delivery of the recombinant HIV-1 clade-C trimeric gp140 envelope protein CN54gp140 within novel rheologically structured vehicles elicits specific immune responses. Vaccine 2009, 27:6791-6798.
14. Cranage M.P., Fraser C.A., Stevens Z., Huting J., Chang M., Jeffs S.A., et al. Repeated vaginal administration of trimeric HIV-1 clade C gp140 induces serum and mucosal antibody responses. Mucosal Immunol 2010, 3:57-68.
15. Su L., Graf M., Zhang Y., von Briesen H., Xing H., Köstler J., et al. Characterization of a virtually full-length human immunodeficiency virus type 1 genome of a prevalent intersubtype (C/B') recombinant strain in China. J Virol 2005, 74:11367-11376.
16. Rodenburg C.M., Li Y., Trask S.A., Chen Y., Decker J., Robertson D.L., et al. Near full-length clones and reference sequences for subtype C isolates of HIV type 1 from three different continents. AIDS Res Hum Retroviruses 2001, 17:161-168.
17. Owen D.H., Katz D.F. A vaginal fluid simulant. Contraception 1999, 59:91-95.
18. Rohan L.C., Sassi A.B. Vaginal drug delivery systems for HIV prevention. AAPS J 2009, 11:78-87.
19. Carpenter JF, Prestrelski SJ, Anchordoguy TJ, Arakawa T. Interactions of stabilizers with proteins during freezing drying and drying. In: Cleland JL, Lauger R, editors. Formulation and delivery of proteins and peptides, American Chemical Society Symposium Series No. 567; 1994, p. 134-47.
20. Carpenter J.F., Pikai M.J., Chang B.S., Randolph T.W. Rational design of stable lyophilized protein formulations: some practical advice. Pharm Res 1997, 14:969-975.
21. Lu S. Heterologous prime-boost vaccination. Curr Opin Immunol 2009, 21:346-351.
22. Li M., Gao F., Mascola J.R., Stamatatos L., Polonis V.R., Koutsoukos M., et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 2005, 79:10108-10125.